Apellis Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
APLS Apellis Pharmaceuticals Inc
AMD Advanced Micro Devices Inc
OTIS Otis Worldwide Corp
GME GameStop Corp
ECF Ellsworth Growth and Income Fund Ltd
SILK Silk Road Medical Inc
HLVX Hillevax Inc
AIZ Assurant Inc
NOTV Inotiv Inc
MYD BlackRock MuniYield
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that is focused on developing therapeutic compounds to treat disease through the inhibition of the complement system. The Company is developing pegcetacoplan with Sobi for systemic administration in several indications, including paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, cold agglutinin disease, and hematopoietic stem cell transplantation thrombotic microangiopathy. The Company's advanced clinical programs targeting component 3 with Phase III clinical trials of its lead product candidate, pegcetacoplan, in multiple indications. Pegcetacoplan is a conjugate of a compstatin analogue, formulated both for ophthalmological administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin.

Closing Price
$55.02
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Heavy Day)
Volume:
2,031,635

10-day average volume:
1,115,864
2,031,635

Exxon board expands to 13 directors; airline, aerospace executives join

4:17 pm ET December 2, 2022 (MarketWatch)
Print

Exxon Mobil Corp. said late Friday that Larry W. Kellner and John D. Harris II have joined its board, which expanded to 13 directors. Kellner is the former chief executive of Continental Airlines, which merged with United Airlines in 2010, and current chairman of the board for Boeing Co. Harris is the former chief executive of Raytheon International Inc., a subsidiary of Raytheon Technologies Co. . Of the 13 directors, 12 are independent, Exxon said. "We welcome both Larry and John to the ExxonMobil board, as the company executes its strategy to grow shareholder value by leading a thoughtful transition to a lower-emissions future, while providing the reliable energy and products the world needs," lead independent director Joseph Hooley said in a statement. Shares of Exxon edged lower in the extended session Friday after ending the regular trading day down 0.9%.

-Claudia Assis

	

(END) Dow Jones Newswires

December 02, 2022 16:17 ET (21:17 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.